Emerging concepts for assessing and predicting treatment-free remission in chronic myeloid leukemia patients.
Massimo BrecciaEmilia ScalzulliSara PepeGioia ColafigliMaria Laura BisegnaMarcello CapriataMaurizio MartelliPublished in: Expert review of hematology (2021)
Median duration of TKI therapy and of deep molecular response are the main prognostic factors identified in most trials and real-life experiences on discontinuation. Immunological pathways have been proposed as possible control on successful TFR as also early molecular response dynamics. Appropriate molecular monitoring by RQ-PCR in the TFR phase has been proposed by several international recommendations and digital droplet PCR (ddPCR) seems to have a possible role in the future for a better identification of candidate to this possible therapeutic strategy.
Keyphrases
- prognostic factors
- chronic myeloid leukemia
- end stage renal disease
- chronic kidney disease
- newly diagnosed
- ejection fraction
- single molecule
- mental health
- peritoneal dialysis
- clinical practice
- tyrosine kinase
- rheumatoid arthritis
- stem cells
- patient reported outcomes
- advanced non small cell lung cancer
- epidermal growth factor receptor
- patient reported